Timing and durability of response to erenumab in patients with episodic migraine

• Published in: Headache Vol. 61; no. 10; pp. 1553 - 1561
• Main Authors: McAllister, Peter J., Turner, Ira, Reuter, Uwe, Wang, Andrea, Scanlon, James, Klatt, Jan, Chou, Denise E., Paiva da Silva Lima, Gabriel
• Format: Journal Article
• Language: English
• Published: United States Wiley Subscription Services, Inc 01.11.2021
• Subjects: Adolescent; Adult; Aged; Antibodies, Monoclonal, Humanized - therapeutic use; Calcitonin Gene-Related Peptide Receptor Antagonists - therapeutic use; calcitonin gene‐related peptide receptor; Cognition; Double-Blind Method; Durability; efficacy; Female; Headache; headache frequency; Humans; Male; Middle Aged; Migraine; Migraine Disorders - drug therapy; Monoclonal antibodies; monoclonal antibody; pain; Patients; Prevention; Reduction; Surveys and Questionnaires; Time Factors; Treatment Outcome; Young Adult; calcitonin gene-related peptide receptor; pain; headache; headache frequency; monoclonal antibody; efficacy

Objective We sought to evaluate temporal response patterns to erenumab treatment in patients with episodic migraine. Background Although many patients treated with erenumab experience onset of efficacy as early as 1 week, clinical benefits of migraine preventive therapies may accrue with continued t...